Issue Information
No one size fits all—Shortening duration of therapy with direct‐acting antivirals for hepatitis C genotype 1 infection
Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus‐infected persons
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension
HIV‐positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C
Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry
Treatment with direct‐acting antiviral agents of hepatitis C virus infection in injecting drug users : A prospective study
Long‐term outcomes of direct acting antivirals in post‐transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis
HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy‐treated HIV/HCV‐co‐infected subjects
Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C : Results at week 144
The impact of hepatitis B virus infection and vaccination on the development of non‐Hodgkin lymphoma
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment‐naïve, noncirrhotic HCV genotype 3‐infected patients